BC
IOVA icon

Bridgefront Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Bridgefront Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,270
Closed -$173K – 470
2023
Q4 		$173K Buy
+21,270
New +$111K 0.13% 311
2023
Q2 		– Sell
-38,528
Closed -$235K – 565
2023
Q1 		$235K Buy
+38,528
New +$266K 0.14% 284
2021
Q3 		– Sell
-9,391
Closed -$244K – 508
2021
Q2 		$244K Sell
9,391
-2,287
-20% -$59.4K 0.09% 428
2021
Q1 		$370K Buy
+11,678
New +$484K 0.12% 350

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bridgefront Capital's IOVA Position: Q1 2024 in Review

Bridgefront Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 21,270 shares — an estimated $173K sold.

Bridgefront Capital first reported a position in IOVA in Q1 2021 and held it in 4 quarters. The position peaked at $370K in Q1 2021. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

  • Bridgefront Capital reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Bridgefront Capital sold 21,270 Iovance Biotherapeutics shares in Q1 2024, an estimated $173K.
  • Bridgefront Capital first reported a position in Iovance Biotherapeutics in Q1 2021 and held it in 4 quarters.
  • Bridgefront Capital's Iovance Biotherapeutics position peaked at $370K in Q1 2021.
  • 273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on Bridgefront Capital's 13F filing for Q1 2024, filed 15 May 2024.